Inventor · disambiguated record
Floris Louis Van Delft
Also filed as: VAN DELFT FLORIS LOUIS
31 granted patents·27 pending applications·422 citations·filing 2011–2025
96Inventor score
Top patents by PatentIndex Score
58 records- 0198US9504758B2Modified antibody, antibody-conjugate and process for the preparation thereofSYNAFFIX BV·Filed 2015·Granted Nov 29, 2016·65 cites·20 claims
- 0297US10266502B2Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyneSYNAFFIX BV·Filed 2015·Granted Apr 23, 2019·78 cites·15 claims
- 0397US10239807B2Fused cyclooctyne compounds and their use in metal-free click reactionsSYNAFFIX BV·Filed 2015·Granted Mar 26, 2019·57 cites·21 claims
- 0497US9222940B2Fused cyclooctyne compounds and their use in metal-free click reactionsSYNAFFIX BV·Filed 2014·Granted Dec 29, 2015·91 cites·27 claims
- 0594US8859629B2Fused cyclooctyne compounds and their use in metal-free click reactionsVAN DELFT FLORIS LOUIS·Filed 2011·Granted Oct 14, 2014·80 cites·24 claims
- 0692US9636421B2Sulfamide linker, conjugates thereof, and methods of preparationSYNAFFIX BV·Filed 2016·Granted May 2, 2017·14 cites·15 claims
- 0791US11338043B2Antibody-conjugates with improved therapeutic index for targeting HER2 tumours and method for improving therapeutic index of antibody-conjugatesSYNAFFIX BV·Filed 2017·Granted May 24, 2022·8 cites·10 claims
- 0890US10072096B2Modified glycoprotein, protein-conjugate and process for the preparation thereofSYNAFFIX BV·Filed 2014·Granted Sep 11, 2018·9 cites·15 claims
- 0990US9988661B2Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from A β(1,4)-N-acetylgalactosaminyltransferaseSYNAFFIX BV·Filed 2016·Granted Jun 5, 2018·5 cites·11 claims
- 1090US2025084022A1Fused cyclooctyne compounds and their use in metal-free click reactionsSYNAFFIX BV·Filed 2024·Application pending·0 cites
- 1188US10792369B2Sulfamide linker, conjugates thereof, and methods of preparationSYNAFFIX BV·Filed 2017·Granted Oct 6, 2020·3 cites·25 claims
- 1286US11547763B2Enediyne conjugatesSYNAFFIX BV·Filed 2020·Granted Jan 10, 2023·3 cites·25 claims
- 1386US2025177554A1Modified antibody, antibody-conjugate and process for the preparation thereofSYNAFFIX BV·Filed 2024·Application pending·0 cites
- 1485US11850286B2Sulfamide linker, conjugates thereof, and methods of preparationSYNAFFIX BV·Filed 2020·Granted Dec 26, 2023·1 cites·28 claims
- 1584US11358921B2Fused cyclooctyne compounds and their use in metal-free click reactionsSYNAFFIX BV·Filed 2019·Granted Jun 14, 2022·1 cites·17 claims
- 1683US9987373B2Modified glycoprotein, protein-conjugate and process for the preparation thereofSYNAFFIX BV·Filed 2014·Granted Jun 5, 2018·3 cites·19 claims
- 1782US11299759B2Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from a β(1,4)-n-acetylgalactosaminyltransferaseSYNAFFIX BV·Filed 2018·Granted Apr 12, 2022·1 cites·9 claims
- 1879US11168085B2Process for the cycloaddition of a hetero(aryl) 1,3-dipole compound with a (hetero)cycloalkyneSYNAFFIX BV·Filed 2015·Granted Nov 9, 2021·2 cites·28 claims
- 1978US11951175B2Bioconjugates containing sulfamide linkers for use in treatmentSYNAFFIX BV·Filed 2017·Granted Apr 9, 2024·1 cites·21 claims
- 2076US12180145B2Fused cyclooctyne compounds and their use in metal-free click reactionsSYNAFFIX BV·Filed 2022·Granted Dec 31, 2024·0 cites·27 claims
- 2174US12049656B2Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from a β(1,4)-n-acetylgalactosaminyltransferaseSYNAFFIX BV·Filed 2022·Granted Jul 30, 2024·0 cites·14 claims
- 2274US2024398971A1Bioconjugates containing sulfamide linkers for use in treatmentSYNAFFIX BV·Filed 2024·Application pending·0 cites
- 2372US2025304611A1Synthesis of 6-azido-6-deoxy-2-n-acetyl-hexosamine-nucleoside diphosphateSYNAFFIX BV·Filed 2025·Application pending·0 cites
- 2471US12194107B2Modified antibody, antibody-conjugate and process for the preparation thereofSYNAFFIX BV·Filed 2020·Granted Jan 14, 2025·0 cites·22 claims
- 2570US2023127659A1Antibody-conjugates with improved therapeutic index for targeting her2 tumours and method for improving therapeutic index of antibody-conjugatesSYNAFFIX BV·Filed 2022·Application pending·0 cites
- 2668US12281135B2Synthesis of 6-azido-6-deoxy-2-n-acetyl-hexosamine-nucleoside diphosphateSYNAFFIX BV·Filed 2022·Granted Apr 22, 2025·0 cites·20 claims
- 2768US11713453B2Enzymes for trimming of glycoproteinsSYNAFFIX BV·Filed 2020·Granted Aug 1, 2023·0 cites·18 claims
- 2866US12084448B2Process for the cycloaddition of a (hetero)aryl 1,3-dipole compound with a (hetero)cycloalkyneSYNAFFIX BV·Filed 2021·Granted Sep 10, 2024·0 cites·18 claims
- 2965US12440573B2Antibody-conjugates for targeting of tumours expressing PTK7SYNAFFIX BV·Filed 2024·Granted Oct 14, 2025·0 cites·9 claims
- 3065US2023346965A1Enediyne conjugatesSYNAFFIX BV·Filed 2023·Application pending·0 cites
- 3165US2025090679A1Antibody-conjugates for targeting of tumours expressing trop-2SYNAFFIX BV·Filed 2024·Application pending·0 cites
- 3265US2023405143A1Tyrosine-based antibody conjugatesSYNAFFIX BV·Filed 2023·Application pending·0 cites
- 3363US2023338562A1Methods for the preparation of linker payload constructsSYNAFFIX BV·Filed 2022·Application pending·0 cites
- 3463US2023226208A1Methods for the preparation of bioconjugatesSYNAFFIX BV·Filed 2023·Application pending·0 cites
- 3562US11957763B2Sulfamide linkers for use in bioconjugatesSYNAFFIX BV·Filed 2020·Granted Apr 16, 2024·0 cites·20 claims
- 3662US10745488B2Modified antibody, antibody-conjugate and process for the preparation thereofSYNAFFLIX BV·Filed 2013·Granted Aug 18, 2020·0 cites·35 claims
- 3761US2025082770A1Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigenSYNAFFIX BV·Filed 2024·Application pending·0 cites
- 3861US2023190951A1Conjugates of antibodies an immune cell engagersSYNAFFIX BV·Filed 2022·Application pending·0 cites
- 3961US2023330245A1Antibody-exatecan conjugatesSYNAFFIX BV·Filed 2023·Application pending·0 cites
- 4060US11590239B2Antibody-conjugates with improved therapeutic index for targeting CD30 tumours and method for improving therapeutic index of antibody-conjugatesSYNAFFIX BV·Filed 2017·Granted Feb 28, 2023·0 cites·9 claims
- 4160US2023355791A1Glycan-conjugated antibodies binding to fc-gamma receptorSYNAFFIX BV·Filed 2023·Application pending·0 cites
- 4259US2023364262A1Via cycloaddition bilaterally functionalized antibodiesSYNAFFIX BV·Filed 2022·Application pending·0 cites
- 4359US2019225706A1Modified glycoprotein, protein-conjugate and process for the preparation thereofSYNAFFIX BV·Filed 2018·Application pending·0 cites
- 4459US2023114866A1Via cycloaddition bilaterally functionalized antibodiesSYNAFFIX BV·Filed 2022·Application pending·0 cites
- 4559US2025262314A1Multifunctional antibodiesSYNAFFIX BV·Filed 2022·Application pending·0 cites
- 4659US2025205353A1Antibody-conjugates for targeting of tumours expressing nectin-4SYNAFFIX BV·Filed 2023·Application pending·0 cites
- 4758US10874746B2Sulfamide linkers for use in bioconjugatesSYNAFFIX BV·Filed 2017·Granted Dec 29, 2020·0 cites·14 claims
- 4858US2022096652A1Acetal-based cleavable linkersSYNAFFIX BV·Filed 2021·Application pending·0 cites
- 4957US10858641B2Enzymes for trimming of glycoproteinsSYNAFFIX BV·Filed 2017·Granted Dec 8, 2020·0 cites·15 claims
- 5057US2025367315A1Antibody-drug conjugates with masked pbd dimersSYNAFFIX BV·Filed 2025·Application pending·0 cites
Showing the top 50 of 58 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Floris Louis Van Delft files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →